Palatin Technologies (PTN) Stock Price, Quote & News

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 495 2200

Fax: 609 495 2202

Website: palatin.com

Address:

Cedar Brook Corporate Center, 4-B Cedar Brook Drive, Cranbury, United States

Warmark Sep. 9 at 12:52 AM

$PTN Bankruptcy is on the way!

0 · Reply

prismmarketview Sep. 8 at 4:27 PM

Prism Midday Movers: Tech and Energy Shine While Biotechs Slide Planet Labs ( $PL) up 36.2% Shares soared more than 35% today, hitting a fresh 52-week high after reporting record Q2 revenue of $73.4M (+20% YoY). QuantumScape Corp ( $QS) up 26% Shares surged 26% after showcasing its QSE-5 solid-state battery in a Ducati motorcycle at IAA Mobility. The demo, backed by Volkswagen’s PowerCo and Ducati, highlighted faster charging, higher energy density, and stronger safety. Other PRISM Mid-Day Movers: Shattuck Labs, Inc. ( $STTK) Up 19.9% Palatin Technologies, Inc. ( $PTN) Down 44% TFF Pharmaceuticals ( $TFFP) Down 60% https://prismmarketview.com/prism-midday-movers-tech-and-energy-shine-while-biotechs-slide/

0 · Reply

Stocks787 Sep. 8 at 4:27 PM

$PTN 1.00

0 · Reply

Stocks787 Sep. 5 at 1:54 PM

$PTN 1

0 · Reply

BullDonald Sep. 5 at 11:22 AM

$PTN Like I SAW it Comming... Spana Did it. Today i did not beleive what m seeing sfor a moment .. it's OTC now... Try to get ur ur money some how... befor they dissapear. U dont want to be in a situation lilke : $NBRVF Once in OTC u are Blind whats going on behind the scene. they make money under the table and can sell everything for penny, Retail gets Nothing... BE WARNNED. Third stock that was in my Portfolio once goes.... BK.

2 · Reply

Warmark Sep. 5 at 12:44 AM

$PTN Who wants to place bets that this stock and company will be worth less than 1.00 sometime in 2026?

0 · Reply

Stocks787 Sep. 4 at 7:42 PM

$PTN 4 a 5

0 · Reply

Stocks787 Sep. 4 at 2:32 PM

$PTN 1.00

0 · Reply

Stocks787 Sep. 3 at 10:46 PM

$PTN $1.00 Buy

0 · Reply

commanche Aug. 29 at 2:41 PM

$PTN if this is not prime example of junk, i dont know what is

0 · Reply

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025, 5:20 PM EDT - 4 months ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025, 8:15 AM EDT - 4 months ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:00 AM EDT - 4 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 5, 2025, 7:30 AM EDT - 4 months ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Apr 29, 2025, 7:30 AM EDT - 4 months ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 17, 2025, 7:30 AM EDT - 5 months ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 14, 2025, 7:00 AM EDT - 5 months ago

Palatin Appeals NYSE American Notice of Delisting

Apr 10, 2025, 4:01 PM EDT - 5 months ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 7:30 AM EDT - 5 months ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Mar 31, 2025, 7:30 AM EDT - 5 months ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 28, 2025, 7:30 AM EDT - 5 months ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 25, 2025, 7:30 AM EDT - 6 months ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Feb 15, 2025, 5:41 AM EST - 7 months ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Feb 13, 2025, 7:30 AM EST - 7 months ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 10, 2025, 4:00 PM EST - 7 months ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 7, 2025, 8:00 AM EST - 7 months ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 6, 2025, 7:30 AM EST - 7 months ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Jan 28, 2025, 7:30 AM EST - 7 months ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Dec 19, 2024, 7:30 AM EST - 9 months ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 16, 2024, 7:30 AM EST - 9 months ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Nov 25, 2024, 7:30 AM EST - 10 months ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 14, 2024, 12:49 PM EST - 10 months ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 7:30 AM EST - 10 months ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 8, 2024, 9:57 AM EST - 10 months ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 4, 2024, 7:30 AM EST - 11 months ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Oct 31, 2024, 7:30 AM EDT - 11 months ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 24, 2024, 7:30 AM EDT - 11 months ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 11 months ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 7, 2024, 4:15 PM EDT - 1 year ago

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 1, 2024, 2:55 PM EDT - 1 year ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Aug 28, 2024, 7:30 AM EDT - 1 year ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 22, 2024, 7:30 AM EDT - 1 year ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

May 15, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

May 2, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

$Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024$

Apr 8, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Feb 28, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 15, 2024, 2:49 PM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript

Feb 15, 2024, 7:30 AM EST - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Feb 9, 2024, 7:30 AM EST - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Feb 5, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 1, 2024, 4:00 PM EST - 1 year ago

Palatin Announces Closing of $10 Million Registered Direct Offering

Warmark Sep. 9 at 12:52 AM

$PTN Bankruptcy is on the way!

0 · Reply

prismmarketview Sep. 8 at 4:27 PM

0 · Reply

Stocks787 Sep. 8 at 4:27 PM

$PTN 1.00

0 · Reply

Stocks787 Sep. 5 at 1:54 PM

$PTN 1

0 · Reply

BullDonald Sep. 5 at 11:22 AM

2 · Reply

Warmark Sep. 5 at 12:44 AM

$PTN Who wants to place bets that this stock and company will be worth less than 1.00 sometime in 2026?

0 · Reply

Stocks787 Sep. 4 at 7:42 PM

$PTN 4 a 5

0 · Reply

Stocks787 Sep. 4 at 2:32 PM

$PTN 1.00

0 · Reply

Stocks787 Sep. 3 at 10:46 PM

$PTN $1.00 Buy

0 · Reply

commanche Aug. 29 at 2:41 PM

$PTN if this is not prime example of junk, i dont know what is

0 · Reply

Warmark Aug. 27 at 8:15 PM

$PTN This stock and company are an absolute dumpster fire. Why would any intelligent person invest here after 2 reverse splits, the last one being 50/1???

0 · Reply

JOHNB21400 Aug. 27 at 6:05 PM

$PTN 10.87 and moving up

0 · Reply

MoMoney80 Aug. 27 at 12:02 AM

$PTN been awhile aince i checked in here. Whats this POS been up to?

1 · Reply

JOHNB21400 Aug. 26 at 6:52 PM

$PTN The price is locked at 10.66. I suspect movement back to the New York board. Then we can have new news.

0 · Reply

Badolo83 Aug. 22 at 5:39 PM

$PTN meh.. POS that has always been and always will continue destroying shareholder value.

0 · Reply

Stocks787 Aug. 21 at 9:17 PM

$PTN How many cents is this price worth?

0 · Reply

kikmontero Aug. 21 at 12:20 PM

$PTN This is in OTC guys. Nobody cares the news and no institution invests here

0 · Reply

healthymorty33 Aug. 20 at 11:05 PM

$PTN All I've seen with the Boehringer Ingelheim deal is the "up to $327 million" number, has the actual guaranteed money been reported?

0 · Reply

JOHNB21400 Aug. 20 at 3:35 AM

$PTN We fondly have extremely BULLISH.

0 · Reply

Zeusgodmd Aug. 19 at 10:42 PM

$PTN no more share dilution only going up from here. Eye med then gi med and weight med. all aboard

0 · Reply

JOHNB21400 Aug. 19 at 9:50 PM

$PTN In order to exceed to extremely bullish have to have a score higher than 75. Announce another drug findings an we will be there.

0 · Reply

Warmark Aug. 19 at 7:16 PM

$PTN We are back up to 22 cents!! Woot! Doesn't anyone wonder why this news didn't come out BEFORE the reverse split that screwed investors? Hmmm?

0 · Reply

Market Cap	2.45M
Revenue (ttm)	4.49M
Net Income (ttm)	-29.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-662.36%
Debt to Equity Ratio	0.00

Volume	14,571,800
Avg Vol	3,131,146
Day's Range	N/A - N/A
Shares Out	26.01M
Stochastic %K	5%
Beta	0.94
Analysts	Strong Sell
Price Target	$7.00